Alnylam Pharmaceuticals Inc’s filing revealed that its Chief Executive Officer Greenstreet Yvonne unloaded Company’s shares for reported $4.2 million on Aug 20 ’24. In the deal valued at $280.00 per share,15,000 shares were sold. As a result of this transaction, Greenstreet Yvonne now holds 73,441 shares worth roughly $19.59 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Greenstreet Yvonne bought 15,000 shares, generating $4,200,000 in total proceeds.
Before that, Fitzgerald Kevin Joseph sold 22,025 shares. Alnylam Pharmaceuticals Inc shares valued at $5,968,516 were divested by the CSO & EVP, Head of Research at a price of $270.99 per share. As a result of the transaction, Fitzgerald Kevin Joseph now holds 12,881 shares, worth roughly $3.44 million.
Goldman upgraded its Alnylam Pharmaceuticals Inc [ALNY] rating to a Buy from a a Neutral in a research note published on August 16, 2024; the price target was increased to $370 from $198. A number of analysts have revised their coverage, including Goldman’s analysts, who decreased its forecast for the stock in mid February from “a Buy” to “a Neutral”. Wolfe Research began covering ALNY with “Peer perform” recommendation on February 15, 2024. Wells Fargo started covering the stock on December 08, 2023. It rated ALNY as “an Equal weight”.
Price Performance Review of ALNY
On Monday, Alnylam Pharmaceuticals Inc [NASDAQ:ALNY] saw its stock fall -0.46% to $266.77. Over the last five days, the stock has lost -3.00%. Alnylam Pharmaceuticals Inc shares have risen nearly 39.37% since the year began. Nevertheless, the stocks have risen 49.28% over the past one year. While a 52-week high of $287.55 was reached on 08/29/24, a 52-week low of $141.98 was recorded on 04/25/24. SMA at 50 days reached $266.71, while 200 days put it at $197.31.
Levels Of Support And Resistance For ALNY Stock
The 24-hour chart illustrates a support level at 264.43, which if violated will result in even more drops to 262.09. On the upside, there is a resistance level at 268.83. A further resistance level may holdings at 270.89. The Relative Strength Index (RSI) on the 14-day chart is 47.54, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -4.43, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 83.31%. Stochastics %K at 24.15% indicates the stock is a holding.
How much short interest is there in Alnylam Pharmaceuticals Inc?
A steep rise in short interest was recorded in Alnylam Pharmaceuticals Inc stocks on 2024-09-13, dropping by 63147.0 shares to a total of 4.45 million shares. Yahoo Finance data shows the prior-month short interest on 2024-08-15 was 4.52 million shares. There was a decline of -1.42%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 08, 2023 when Wells Fargo began covering the stock and recommended ‘”an Equal weight”‘ rating .
